Search - tctmd.com

Displaying 21 - 33 of 33

Sort: Relevancy | Date

Presentation TCT 2015

The PCSK9 Inhibitor Revolution

Presenter: Frederick Feit, C. Michael Gibson, Norman E. Lepor

October 15, 2015

Presentation TCT 2015

Hyperlipidemic Therapy: From Statins to PCSK9 Inhibitors

Presenter: George D. Dangas, Paul A. Gurbel, Joshua W. Knowles

October 13, 2015

Presentation TCT 2015

Adjuvant Pharmacotherapy With Ranolazine In Patients With Ischemic Heart Disease

Presenter: Bernard J. Gersh, Stephen D. Wiviott, Giora Weisz

October 13, 2015

Presentation TCT 2015

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

Presenter: Bernard J. Gersh, Stephen D. Wiviott

October 13, 2015

Presentation TCT 2015

PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events

Presenter: Bernard J. Gersh, Stephen D. Wiviott, Evan A. Stein

October 13, 2015

Presentation TCT 2015

Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic?

Presenter: Bernard J. Gersh, Stephen D. Wiviott, David J. Maron

October 13, 2015

Presentation TCT 2015

Will PCSK9 Inhibitors Transform the Natural History of Atherosclerosis?

Presenter: Gregg W. Stone, Renu Virmani, Philippe Gabriel Steg

October 12, 2015

Presentation TCT 2014

PCSK9 Inhibitors: Comparison of Agents and a Systematic Review

Presenter: Ori Ben-Yehuda, Harvey D. White, Roxana Mehran, Evan A. Stein

September 15, 2014

Presentation TCT 2014

Systemic Therapies for the At-Risk Patient: From Darapladib to Anti-inflammatories and PCSK9 Inhibitors

Presenter: Valentin Fuster, Patrick W. Serruys, Harvey D. White

September 14, 2014

News Conference News TCT 2014

Experts Look to Big Data to Identify New Therapeutic Targets for CVD

September 14, 2014

Presentation TCT 2013

PCSK9 Inhibitors: Too Good to Be True?

Presenter: Evan Stein

October 30, 2013

Presentation TCT 2012

PCSK9 Inhibitors: The Holy Grail?

Presenter: Evan Stein

October 23, 2012

Presentation TCT 2012

Late Breaking Clinical Trials: STAMPEDE (Bariatric Surgery) and PCSK9 (LDL Reduction)

Presenter: Elizabeth Jackson

October 23, 2012

Advertisement

The PCSK9 Inhibitor Revolution

Hyperlipidemic Therapy: From Statins to PCSK9 Inhibitors

Adjuvant Pharmacotherapy With Ranolazine In Patients With Ischemic Heart Disease

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events

Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic?

Will PCSK9 Inhibitors Transform the Natural History of Atherosclerosis?

PCSK9 Inhibitors: Comparison of Agents and a Systematic Review

Systemic Therapies for the At-Risk Patient: From Darapladib to Anti-inflammatories and PCSK9 Inhibitors

Experts Look to Big Data to Identify New Therapeutic Targets for CVD

PCSK9 Inhibitors: Too Good to Be True?

PCSK9 Inhibitors: The Holy Grail?

Late Breaking Clinical Trials: STAMPEDE (Bariatric Surgery) and PCSK9 (LDL Reduction)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content